The prognosis for patients with grade III-IV astrocytomas is poor. Median survival for patients with such following major surgery and radical radiotherapy with or without chemotherapy remains of the order of 6 months and survival beyond 3 years is rare (see reviews by Bloom, 1982; Walker & Gehan, 1976) . There is, therefore, considerable interest in finding more effective therapies for these tumours which may also prove of value for other intra-cranial gliomas in adults and children.
Recent results suggest that treatment of some tumour types with various preparations of Interferon (IFN) might result in occasional clinical success (Gutterman et al., 1980) . Experimental support for this suggestion derives, in part, from the observations that IFNs were found capable of inhibiting the in vitro growth of a wide variety of both normal and malignant cell types (Balkwill & Oliver, 1977) . They have also been shown to regulate the immune system (Gresser, 1977) and to induce differentiated characteristics in some nervous system tumour cell cultures (Bal de Kier Joffe et al., 1979) .
The effects of IFN on the in vivo growth of both transplantable rodent tumours and human tumour xenografts are varied, in that IFN treatment can either inhibit tumour incidence or growth in some rodent tumours, or have no effect at all in others (for review see Priestman, 1979) . In the case of human tumour xenografts, IFN treatment has been found to increase the period between implantation and perceptible growth in two out of three human breast cancer xenografts in Nude mice (Balkwill et al., 1980) . De Clerq et al. (1978) found that IFN had no effect on the growth of human tumour xenografts derived from a fibrosarcoma and a melanoma.
With (Morgan et al., 1983) . (Darling, et al., 1982) . (Table I) (Darling et al., 1983) Animals The mice used in these experiments were from the inbred CBA/Ca strain, bred and maintained at the Chester BeattyResearch Laboratories. Theywere T-cell deprived and implanted with tumour as described previously (Bradley et al., 1978) . The method used to estimate HLI sensitivity of monolayer cell cultures was that of Morgan et al. (1983) . Cell cultures in exponential growth were treated with HLI at various dilutions in replicate micro-titration plates. Residual viability was assessed by [35S]-methionine incorporation and autofluorography in situ at 2 time points. One of the replicate plates was processed for autofluorography immediately following IFN treatment, whilst the second plate was washed free of IFN and re-fed with fresh growth medium. Culture was continued for a further 2-3 cell population-doubling times. At this point the second plate was processed for autofluorography. In this way it proves possible to examine the reversibility of drug treatment.
Multicellular spheroid assay of IFN activity Single spheroids were removed using a sterile finelydrawn Pasteur pipette and transferred to agarcoated wells of a micro-titration plate. Each well was then fed with 0.1-0.2 ml of fresh growth medium. Ten spheroids were used in each of the control and treatment groups. After 1-2 days growth, the volume of each spheroid was determined by measuring the two perpendicular diameters and calculating the volume using the formula V= -x (mean diameter)3. 6 Medium was then removed from test wells and replaced with the appropriate volume of HLI dilution in growth medium. After 24-48 h incubation, the HLI was removed and replaced with fresh growth medium. The volumes of the spheroids were determined every 24 h, up to 11 days post-treatment and growth curves constructed. Spheroid volume doubling times (TD) were calculated and HLI sensitivity determined by calculating a growth delay index (GDI) from the following formula (Nowak et al., 1978) . Xenograft assay of IFN sensitivity HLI at a concentration of 2x 15UmlP1, or diluent (1% HIFCS in PBS), was administered by daily s.c. injections of 0.1 ml to the inguinal region (Balkwill et al., 1980) . Treatment was started as soon as individual mice were determined to have palpably growing tumours, -2 mm in diameter. Volumes of tumours were determined by measuring 3 perpendicular axes of each tumour and substituting in the equation:
Growth curves were constructed and GDI figures obtained by using the same method as for the spheroids.
Results
In vitro studies Monolayer cultures Cell cultures derived from two high-grade astrocytomas obtained during surgical biopsy were treated with IFN and their sensitivity to this drug was established at the 2 time-points defined in the Methods section. Tumour 14/81, the grade III astrocytoma, had a maximum inhibition of protein synthesis of 48% of control values immediately after IFN treatment and 42% after 28 h recovery in fresh medium. The grade IV astrocytoma, 15/81, initially showed a slight stimulation of protein synthesis compared with control cultures, which was lost after recovery in fresh medium. Two cell cultures derived from astrocytoma xenografts were also examined. For tumour 496, the maximum inhibition of protein synthesis was 70% at an IFN concentration of 1000Uml-P immediately after drug removal and the ID50 (concentration of drug which inhibited protein synthesis by 50%) was 30UmlP1. However, after recovery, the maximum inhibition at 1000 U ml-1 remained unchanged at 70 U ml-' but the ID50 had increased by over 10-fold, to 340 U ml 1. Tumour 508, on the other hand, appeared more resistant to treatment with HLI. Immediately after IFN removal, the maximum inhibition at 1000 U ml1 was 27% and after recovery in fresh medium there was no measurable inhibition of protein synthesis. Table III illustrate that the maximum number of tumour volume doubling times saved was only 1.7. This occurred in the multicellular spheroids that were exposed to 102 UmlP-HLI.
In vivo studies
The experimental design, including information on the number of tumours used in these studies is indicated in Table IV . . It has been suggested that the inhibition of specific proteins is in some way responsible for the antiproliferative effect of IFNs. In glioma cells the synthesis of a specific protein may be affected which causes a generalised inhibition of growth. In any event our results indicate that this "block", if it exists in our systems, seems to be rapidly reversible upon incubation in fresh medium. This latter aspect is in agreement with Kuwata et al. (1976) who reported that although HLI was able to inhibit the growth of two transformed human embryonic cell lines, recovery in fresh medium was possible. From previous studies on the patterns of response to cytotoxic drugs in vitro (Thomas et al., 1982: Darling & Thomas in preparation) , it is apparent that if a culture derived from a patient's tumour rapidly loses sensitivity to a drug upon recovery in fresh medium after drug treatment (Morgan et al., 1983) it is an indication that the patient's tumour will not respond to that drug clinically. The binding and entry of IFN to cells has been suggested as one mechanism for the apparent resistance of certain cell cultures (Kuwata et al., 1976; Berman & Vilcek, 1974) whilst other authors have suggested that the proliferative state of cells in culture may be an important factor which controls IFN sensitivity (Horoszewicz et al., 1979 : Creasey et al., 1980 . In our monolayer experiments, the cells were treated whilst in exponential growth, which may partially account for their resistance to IFN. On the other hand cells growing as spheroids are not all in cycle (Sutherland & Durand 1976) and hence, possibly, the cycle-specific effects of IFN should be more noticeable in this model system, but this was not the case. Indeed, if noncycling cells were much more sensitive than cycling cells, then tumours growing as xenografts should respond.
HLI had no observable effect on the growth of two gliomas growing as xenografts in immunedeprived mice, either when administered alone or in conjunction with BCNU.
The route of injection (s.c.) and dosage may not have been optimal. However, Balkwill et al. (1980) using the same dosage, route of administration and schedule reported significant anti-tumour activity of Namalwa Human Lymphoblastoid IFN (Darling, unpublished observations) .
For both the in vitro and in vivo experiments, it is possible that the tumours examined could have been uniformly resistant to drug therapy. When the xenografts were treated in vivo with either Procarbazine or BCNU, responses were seen, which in the case of the grade IV-derived tumour resulted in complete regression of the majority of the tumours. These results are in accordance with our wider observations on the drug-sensitivity of human glioma xenografts (observations to be published).
The inclusion of HLI into the chemotherapy schedule had no observable effect. With regard to the grade IV tumour, it might be supposed that the effects of HLI could have manifested themselves in assisting the killing of the relatively small number of cells remaining after BCNU therapy. The fact that two tumours treated with this combination subsequently regrew suggests that this does not occur.
Interferon not only has anti-proliferative effects, but may also have an effect on cells of the immune system. Gresser and his colleagues (1972) have shown that L1210 cells although apparently resistant to the anti-cellular effects of IFN in vitro, were inhibited in vivo. Further work has established that this may be due to a regulation of effector cells in the immune system (Lindahl et al., 1972) . Indeed a recent series of reports (Ikic et al., 1981a,b,c) describes substantial benefits obtained by treating a variety of human tumours with intra-tumoural injections of HLI. The suggestion is that HLI administration by this route is indirectly effective by inducing reactivity of tumour stroma (mesenchyme) and regional lymph nodes. If the action of HLI in vivo is via the stromal elements, this would need to be examined further, particularly in the light of a recent report (Salford et al., 1981) , which describes tumour encapsulation and a decrease in histological grading following intratumoural injections of HLI into high-grade cerebral gliomas.
Recent reports of clinical experience with this agent seem to confirm the lack of clinical benefits. Sawada et al. (1982) , using systemically administered IFN failed to demonstrate an unequivocal effect in glioma patients. This may, of course, be due to incomplete penetration into the brain tumour. This area has not been extensively studied. It is apparent that IFN does not pass the intact blood/CSF barrier in significant amounts (Jordan et al., 1974) and there is no information as to the penetration of IFN through the partially disrupted blood/brain barrier associated with the growth of a malignant glioma. Even if IFN is effective by direct modulation of the systemic immune-response, this immunological advantage may not reach the brain if it retains partial immunological privilege (Darling et al., 1981) .
The results obtained from this series of experiments designed to examine the possible benefits of HLI in glioma therapy, do not suggest that this drug, given systemically, even in combination with cytotoxic drugs cytotoxic drugs has any appreciable anti-proliferative effects. Unless any substantial effect on the tumour stroma or immune response can be demonstrated it is unlikely that IFN will have any significant role to play in the clinical treatment of gliomas.
